Immunogen | IMGN - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
AbbVie USD 4.38B 1.92B 2025-09
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Astellas Pharma JPY 133.96B 29.77B 2025-12
AstraZeneca USD 3.24B 117M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Exelixis USD 252.69M 275K 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -4.85M 4.39M 2024-09
Intrexon USD -60.48M 27.09M 2024-06
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
MacroGenics USD 16.82M 52.97M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 6.23B 2025-12